Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACANYA vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acanya is a combination of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and benzoyl peroxide, an oxidizing agent with bactericidal and keratolytic activity. Benzoyl peroxide exerts its effect by releasing free radical oxygen that oxidizes bacterial proteins and has been shown to reduce Propionibacterium acnes.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
FDA-approved for the topical treatment of acne vulgaris in patients 12 years and older
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Apply a pea-sized amount to the entire face once daily in the evening, topical.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Clindamycin: after topical application, terminal half-life is approximately 2-3 hours in serum, but clinical relevance is minimal due to low systemic levels. Benzoyl peroxide metabolites have a half-life of ~1-2 hours. The clinical effect is primarily local with sustained antimicrobial and keratolytic activity.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Clindamycin is metabolized primarily by the liver via CYP3A4. Benzoyl peroxide is metabolized to benzoic acid and then excreted in urine.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Acanya (clindamycin phosphate 1.2% and benzoyl peroxide 2.5% gel) is a fixed-dose combination applied topically. Systemic absorption is minimal. Clindamycin: <0.1% of applied dose excreted renally as parent and metabolites. Benzoyl peroxide: metabolized to benzoic acid, which is conjugated and excreted renally; <5% of applied dose appears in urine. Fecal excretion is negligible.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Clindamycin: ~60-94% bound to plasma proteins (albumin and alpha-1-acid glycoprotein). Benzoyl peroxide: not significantly bound; its metabolite benzoic acid is ~35% bound to albumin.
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
After topical application, systemic concentrations are negligible; Vd not applicable for parent compound. For clindamycin after intravenous administration, Vd is ~0.6-1.2 L/kg. For benzoyl peroxide, dermal penetration is limited to stratum corneum and pilosebaceous units.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Topical bioavailability: <5% for clindamycin (due to extensive metabolism in skin and low systemic absorption); benzoyl peroxide is essentially not absorbed systemically (<2%).
100% intravenous; not administered by other routes.
No dose adjustment required for renal impairment; safety in severe renal impairment not established.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
No dose adjustment required for hepatic impairment; use caution in severe hepatic impairment.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Approved for patients aged 12 years and older. For children 12-17 years: apply a pea-sized amount to the entire face once daily.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
No specific dose adjustment; use smallest effective amount due to increased risk of skin atrophy in elderly.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
There is no FDA black box warning for Acanya.
Not applicable; no FDA boxed warning exists for this product.
Colitis: Clindamycin may cause pseudomembranous colitis; discontinue if diarrhea occurs.,Skin irritation: Benzoyl peroxide may cause allergic contact dermatitis and photosensitivity; avoid excessive sun exposure.,For external use only; avoid contact with eyes and mucous membranes.
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Hypersensitivity to clindamycin, benzoyl peroxide, or any component of the formulation.,History of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
No specific food interactions reported. Avoid concurrent use with other topical acne products unless directed.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
ACANYA (clindamycin phosphate 1.2% and benzoyl peroxide 5%) is for topical use. Systemic absorption is minimal; however, clindamycin is FDA Pregnancy Category C. Animal studies show no teratogenicity, but no adequate human studies exist. Benzoyl peroxide is Category C with unknown risk. First trimester: theoretical risk from systemic clindamycin if absorbed; second and third trimesters: minimal risk due to low absorption. No reported human teratogenicity for topical use.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Clindamycin is excreted in human milk after systemic administration; topical application yields negligible systemic levels. M/P ratio not established for topical route. Benzoyl peroxide is not known to be excreted in milk. Risk to infant is low if applied to small areas. Use caution if applied to large areas or broken skin.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
No dosing adjustment required for topical ACANYA in pregnancy. Systemic absorption is low and pharmacokinetic changes in pregnancy are unlikely to alter efficacy or safety. Use standard dosing: apply once daily to affected areas.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
ACANYA (clindamycin 1.2% / benzoyl peroxide 2.5%) is a fixed-dose combination gel for acne vulgaris. Apply once daily; avoid excessive application. May bleach hair or colored fabrics. Counsel patients about skin dryness, peeling, and photosensitivity. Consider alternative if significant irritation occurs.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
Wash affected area gently before applying a thin layer once daily.,Avoid contact with eyes, mouth, lips, and mucous membranes.,May cause skin dryness, peeling, or redness; use moisturizer if needed.,Benzoyl peroxide can bleach hair or colored fabrics; avoid contact.,Use sunscreen daily as this product increases sun sensitivity.,If severe irritation or allergic reaction occurs, stop use and consult doctor.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACANYA vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ACANYA is a Topical Antibiotic that works by Acanya is a combination of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and benzoyl peroxide, an oxidizing agent with bactericidal and keratolytic activity. Benzoyl peroxide exerts its effect by releasing free radical oxygen that oxidizes bacterial proteins and has been shown to reduce Propionibacterium acnes.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACANYA and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACANYA is: Apply a pea-sized amount to the entire face once daily in the evening, topical.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACANYA and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACANYA is classified as Category C. ACANYA (clindamycin phosphate 1.2% and benzoyl peroxide 5%) is for topical use. Systemic absorption is minimal; however, clindamycin is FDA Pregnancy Category C. Animal studies sho. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.